Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
Condition:   Prostate CancerInterventions:   Drug: Degarelix;   Drug: Doxorubicin;   Drug: Ketoconazole;   Drug: Docetaxel;   Drug: EstramustineSponsor:   The University of Texas Health Science Center, HoustonNot yet recruiting - verified July 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 23, 2015 Category: Research Source Type: clinical trials

Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer
Conditions:   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast CancerInterventions:   Behavioral: Telephone-Based Intervention;   Other: Survey Administration;   Other: Laboratory Biomarker AnalysisSponsor:   Ohio State University Comprehensive Cancer CenterRecruiting - verified...
Source: ClinicalTrials.gov - March 23, 2015 Category: Research Source Type: clinical trials

Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification
Condition:   Breast NeoplasmsInterventions:   Drug: Tamoxifen;   Drug: Vorinostat;   Drug: pembrolizumabSponsor:   Pamela MunsterActive, not recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 17, 2015 Category: Research Source Type: clinical trials

Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Patients With Breast Cancer Sensitive to Hormonal Therapy
Condition:   Endocrine Sensitive HER2+/HR+ Breast CancerIntervention:   Drug: PertuzumabSponsors:   Istituto Oncologico Veneto IRCCS;   AS.T.R.O. Association for Translational Research in OncologyRecruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2015 Category: Research Source Type: clinical trials

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer
Conditions:   HER2-positive Breast Cancer;   ER-positive Breast CancerInterventions:   Drug: fulvestrant 500 mg;   Drug: Docetaxel (T) 75 mg/m2 (Taxotere);   Drug: Trastuzumab (H, 8mg/kg;   Drug: Pertuzumab (P, 840 mgSponsor:   Western Regional Medical CenterRecruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2015 Category: Research Source Type: clinical trials

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy
Condition:   Estrogen Receptor Positive Breast CancerIntervention:   Drug: hydroxychloroquineSponsor:   Western Regional Medical CenterRecruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2015 Category: Research Source Type: clinical trials

Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy
Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: everolimus;   Drug: anastrozole;   Drug: letrozole;   Drug: tamoxifen citrate;   Drug: fulvestrant;   Drug: megestrol ...
Source: ClinicalTrials.gov - October 20, 2014 Category: Research Source Type: clinical trials

Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) (PCF)
Condition:   Prostate CancerIntervention:   Device: AR-v7 assaysSponsors:   Duke University;   Weill Medical College of Cornell University;   Johns Hopkins University;   Dana-Farber Cancer Institute;   Memorial Sloan-Kettering Cancer Center;   Epic Sciences;   Prostate Cancer FoundationNot yet recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2014 Category: Research Source Type: clinical trials

Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy
Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: everolimus;   Drug: anastrozole;   Drug: letrozole;   Drug: tamoxifen citrate;   Drug: fulvestrant;   Drug: megestrol ...
Source: ClinicalTrials.gov - October 17, 2014 Category: Research Source Type: clinical trials

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
Condition:   Advanced, Persistent, or Recurrent Endometrial CancerInterventions:   Drug: Everolimus;   Drug: Tamoxifen;   Drug: Letrozole;   Drug: Medroxyprogesterone AcetateSponsors:   Gynecologic Oncology Group;   Novartis PharmaceuticalsNot yet recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2014 Category: Research Source Type: clinical trials

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
Condition:   Advanced, Persistent, or Recurrent Endometrial CancerInterventions:   Drug: Everolimus;   Drug: Tamoxifen;   Drug: Letrozole;   Drug: Medroxyprogesterone AcetateSponsors:   Gynecologic Oncology Group;   Novartis PharmaceuticalsNot yet recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2014 Category: Research Source Type: clinical trials

Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
Condition:   Prostate CancerInterventions:   Biological: DCVAC/PCa;   Drug: Leuprolide acetate;   Drug: Goserelin AcetateSponsor:   Sotio a.s.Active, not recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2014 Category: Research Source Type: clinical trials

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
Condition:   Prostate CancerInterventions:   Drug: Enzalutamide;   Drug: Leuprolide acetate;   Radiation: radiationSponsors:   University of Texas Southwestern Medical Center;   Astellas Pharma US, Inc.Recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 10, 2014 Category: Research Source Type: clinical trials

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
Condition:   Prostate CancerInterventions:   Drug: Enzalutamide;   Drug: Leuprolide acetate;   Radiation: radiationSponsors:   University of Texas Southwestern Medical Center;   Astellas Pharma US, Inc.Recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 10, 2014 Category: Research Source Type: clinical trials

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
Condition:   Prostate CancerInterventions:   Drug: Enzalutamide;   Drug: Leuprolide acetate;   Radiation: radiationSponsors:   University of Texas Southwestern Medical Center;   Astellas Pharma US, Inc.Recruiting - verified May 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 10, 2014 Category: Research Source Type: clinical trials

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Conditions:   Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate CancerInterventions:   Drug: Enzalutamide;   Drug: Goserelin acetate;   Drug: Leuprolide acetate;   Radiation: Radiation therapySponsors:   Thomas Jefferson University;   Astellas Pharma Inc;   Medivation, Inc.Recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2013 Category: Research Source Type: clinical trials

A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer.
Condition:   Prostatic NeoplasmInterventions:   Drug: Metformin;   Drug: PlaceboSponsor:   AHS Cancer Control AlbertaRecruiting - verified May 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2013 Category: Research Source Type: clinical trials

1303GCC: Trastuzmab & Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC
Condition:   Metastatic Breast CancerInterventions:   Drug: Trastuzumab plus Pertuzumab;   Drug: Hormonal Therapy with Anastrozole and Fulvestrant;   Drug: Chemotherapy with EribulinSponsors:   Katherine Tkaczuk;   Genentech, Inc.Recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2013 Category: Research Source Type: clinical trials